株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

MSL (メディカルサイエンスリエゾン) の活動・業績評価チャート

Charting MSL Activity and Performance (2017)

発行 FirstWord 商品コード 520359
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.34円で換算しております。
Back to Top
MSL (メディカルサイエンスリエゾン) の活動・業績評価チャート Charting MSL Activity and Performance (2017)
出版日: 2017年06月01日 ページ情報: 英文
概要

当レポートでは、米国およびEU5カ国の大手医薬品企業のMSL (メディカルサイエンスリエゾン) に調査を行った結果から、MSLの活動内容、存在意義とその評価手法などを調査し、チームの位置付け、対応ブランド数・対応領域、製品上市前・上市後の主な活動、KOL・医師との接触頻度・接触手段、MSLの業績評価項目、存在意義の証明手段などについて、各種データ・分析をまとめています。

MSLの活動

  • 担当ブランド数・責任の範囲
  • MSLへのブランドの割り当てと新製品に関する医師とのディスカッション
  • MSLの上市前・上市後の活動
  • 医師との接触の回数と手法
  • 所要時間:積極的接触 vs 受動的接触

MSLの業績評価

  • 社内のコミュニケーションの頻度と形態
  • MSLの評価のための業績測定項目
  • 外部の価値指標の情報収集法
  • 業績評価の頻度

社内ステークホルダーへの価値の証明

  • MSLの価値の証明:業績測定の有用性
  • MSLの価値の証明:業績測定に関して求められる変化

付録

  • MSLのプロファイル
目次

A unique survey-based report providing key insights and actionable intelligence about MSL activity and performance.

Charting MSL Activity and Performance (2017) distils key findings from one of the most comprehensive surveys of US and EU5 Medical Science Liaison (MSL) personnel. Informed by the responses of 100 MSLs working in top pharma companies, the study identifies critical variations in MSL activity and performance measurement.

Building on the ground-breaking 2015 study, this 2017 version provides comparative analysis to show how priorities and practice have changed over the past two years and where MSLs see further change in the future.

Example of companies that participated in this study

Gain Answers to Critical Questions

  • At what drug development stage is an MSL team established, how many brands do they handle and how does this differ between the US and Europe?
  • How do MSL performance measurement criteria change pre to post launch?
  • Building new KOL relationships is a critical post launch activity, but what outcomes are sought and how is success measured?
  • To what extent do US and European views differ on MSL activity in CME, medical congress attendance, investigator initiated trials and on the provision of support to physicians in relation to patient access and patient education?
  • What performance criteria do MSL experts see as becoming increasingly important over the near term and how has this changed in the last 2 years?
  • How many and at what frequency do MSLs contact KOLs/Physicians and what is the most popular means of communication?
  • How has the rise of new stakeholders changed the way MSL performance is measured?
  • What metrics are companies using to demonstrate MSL value?

Report Deliverables

Your report purchase gives you access to unique data and analysis you can use practically to shape MSL plans and hone performance measurement:

  • Data Study: Over 100 clear and concise charts that depict the current state and future outlook for MSL activity and performance assessment
  • Data Tabulations: All the survey data provided in MS Excel
  • Survey Questionnaire: delivered as a PDF document

Key Takeaways

  • Understand which MSL activities are seen as being most important in the US and Europe
  • Benchmark your own MSL activity plans and identify new ways to improve performance
  • Understand thinking in key areas such as KOL engagement, medical congress attendance and investigator initiated trials
  • Examine how US/European MSLs view the value of delivering scientific presentations to KOLs and physicians, and learn about the decline of this activity in the US
  • Identify the most widely used measurements for evaluating MSL-KOL engagement and feedback
  • Know which performance metrics are preferred for demonstrating value to internal stakeholders
  • Learn how thinking towards measuring MSL performance has changed over the past 2 years
  • Understand the current balance between quantitative and qualitative metrics used to measure
  • MSL performance, and assess signals that may indicate a change in the metrics used in future

About the Survey

Interview Methodology:

Data collected via a 25-minute internet-based questionnaire

Screening Criteria:

Respondents were screened to ensure that they are MSLs or MSL managers / directors who work at a pharmaceutical company ranked in the top 100 by revenue

Sample Distribution:

A total of 100 US-/EU5-based MSLs and MSL managers/directors who work for pharmaceutical companies ranked in the top 100 by revenue

Features of the Survey - Not Available Elsewhere

  • Knowledgeable and detailed insights from 100 senior MSLs in the US and Europe.
  • Practical ideas for improving MSL effectiveness and increasing KOL engagement
  • Valuable benchmarking indicators to assess your MSL programme against peers
  • Critical insights for corporate management needing to ensure effective physician communication, engagement and brand support

Table of Contents

MSL Activities

  • Number of Brands Supported and Areas of Responsibility
  • Assignment of MSLs to Brands and Discussion of New Products with Physicians
  • MSL Pre-Launch and Post-Launch Activities
  • Numbers and Methods of Interactions With Physicians
  • Time Spent on Proactive vs. Reactive Engagement

MSL Performance Measurements

  • Internal Communication Frequency and Format
  • Performance Measurements Used to Evaluate MSLs
  • Methods to Gather Information on External Value Metrics
  • Frequency of Performance Review

Value Demonstration to Internal Stakeholders of MSL Performance Measurements

  • Usefulness of MSL Performance Measurements in Value Demonstration
  • Expected Changes in MSL Performance Measurements in Value Demonstration

Appendix

  • Screeners - MSL profile
Back to Top